Table 1 |
||||||
|
Summary of the relationship between EGFR copy number, expression, and the patients' clinical-pathological characteristics |
||||||
|
clinical- pathological characteristic |
Copy number |
Expression |
||||
|
|
||||||
|
Positive, N/% |
Negative, N/% |
P value |
Positive, N/% |
Negative, N/% |
P value |
|
|
|
||||||
|
Age(years) |
||||||
|
≤35 |
5/10.9 |
4/4.3 |
0.265c |
23/92.0 |
107/93.9 |
1.000c |
|
>35 |
41/89.1 |
89/95.7 |
2/8.0 |
7/6.1 |
||
|
Lymph node metastasis |
||||||
|
Positive |
23/50 |
49/52.7 |
0.765a |
16/64.0 |
56/49.1 |
0.178a |
|
Negative |
23/50 |
44/47.3 |
9/36.0 |
58/50.9 |
||
|
Stage |
||||||
|
0 |
0/0 |
2/2.2 |
0.748a, $ |
1/4.0 |
2/1.8 |
0.450a, $ |
|
I |
10/21.7 |
18/19.4 |
6/24.0 |
21/18.4 |
||
|
II |
25/54.3 |
53/57 |
11/44.0 |
67/58.8 |
||
|
III |
10/21.7 |
20/21.5 |
7/28.0 |
22/20.2 |
||
|
IV |
1/2.2 |
0/0 |
0/0 |
1/0.9 |
||
|
Tumor type |
||||||
|
DCIS |
0/0 |
3/3.2 |
0.551b, & |
1/4.0 |
2/1.8 |
1.000c, & |
|
LCIS |
0/0 |
0/0 |
0/0 |
0/0 |
||
|
IDC |
44/95.7 |
83/89.2 |
23/92.0 |
104/91.2 |
||
|
ILC |
0/0 |
3/3.2 |
0/0 |
3/2.6 |
||
|
Other |
2/4.3 |
4/4.3 |
1/4.0 |
5/4.4 |
||
|
ER |
||||||
|
Positive |
33/71.7 |
72/77.4 |
0.464a |
13/52.0 |
92/80.7 |
0.002a |
|
Negative |
13/28.3 |
21/22.6 |
12/48.0 |
22/19.3 |
||
|
PR |
||||||
|
Positive |
27/58.7 |
54/58.1 |
0.943a |
5/20.0 |
76/66.7 |
0.000a |
|
Negative |
19/41.3 |
39/41.9 |
20/80.0 |
38/33.3 |
||
|
HER2 |
||||||
|
Positive |
9/19.6 |
16/17.2 |
0.733a |
5/20.0 |
29/25.4 |
0.567a |
|
Negative |
37/80.4 |
77/82.8 |
20/80.0 |
85/74.6 |
||
|
Ki-67 (%) |
||||||
|
< 14 |
7/15.2 |
35/37.6 |
0.007a |
17/68.0 |
67/58.8 |
0.393a |
|
> 16 |
39/84.8 |
58/62.4 |
8/32.0 |
47/41.2 |
||
|
Subtypes |
||||||
|
LUMA |
9/19.6 |
28/30.1 |
0.628a, ^ |
4/16.0 |
33/28.9 |
0.010c, ^ |
|
LUMB (HER2-NEG) |
17/37.0 |
32/34.4 |
7/28.0 |
42/36.8 |
||
|
LUMB (HER2-POS) |
10/21.7 |
16/17.2 |
4/16.0 |
22/19.3 |
||
|
HER2 |
2/4.3 |
6/17.2 |
1/4.0 |
7/6.1 |
||
|
Basal-like |
6/13.0 |
4/4.3 |
9/36.0 |
1/0.9 |
||
|
UC |
2/4.3 |
7/7.5 |
0/0 |
9/7.9 |
||
|
Grade |
||||||
|
I |
0/0 |
0/0 |
0.921a, # |
0/0 |
0/0 |
0.001a, # |
|
II |
31/67.4 |
52/55.9 |
10/40.0 |
73/64.0 |
||
|
III |
12/26.1 |
21/22.6 |
13/52.0 |
20/17.5 |
||
|
UC |
3/6.5 |
20/21.5 |
2/8.0 |
21/18.4 |
||
|
|
||||||
|
aP values (two-sided) calculated using Pearson's chi-square test. bP values (two-sided) calculated using Fisher's exact test. cP values (two-sided) calculated using Continuity Correction of Pearson's chi-square test. $Pearson's chi-square test for stage 0-II and III- IV vs. EGFR status. &Fisher's exact test for invasive ductal carcinoma and other types vs. EGFR status. ^Pearson's chi-square test for luminal subtypes and other subtypes vs. EGFR status. #Grade II and III vs. EGFR status. DCIS, ductal carcinoma in-situ; LCIS, lobular carcinoma in-situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; Ki-67, Ki-67 proliferation index; LUMA, luminal A; LUMB (HER2-NEG), luminal B (HER2-negative); LUMB (HER2-POS), luminal B (HER2-positive); UC, unclassified. |
||||||
|
Lv et al. Diagnostic Pathology 2011 6:118 doi:10.1186/1746-1596-6-118 |
||||||
